1932

Abstract

Billions of individuals worldwide have benefited from the unprecedented large-scale rollout of COVID-19 vaccines. Given the sheer number of people that have received these vaccines, it is not surprising that rare side effects are reported that were not previously detected in the phase III vaccine trials. This review addresses one rare complication called SARS-CoV-2 vaccination-induced thrombotic thrombocytopenia (VITT). It occurs in approximately 1/50,000 to 1/100,000 recipients of the adenovirus vector–based COVID-19 vaccines made by AstraZeneca-Oxford or Johnson & Johnson. Information on VITT syndrome was disseminated quickly via social media and publications after it was first discovered. Initial observations associating VITT with specific patient populations, thrombus locations, and outcomes associated with heparin therapy have since been refined with additional clinical experience. In this review, we discuss what is currently known about the incidence, pathophysiology, diagnosis, and treatment of VITT.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-043021-015237
2023-01-27
2024-10-13
Loading full text...

Full text loading...

/deliver/fulltext/med/74/1/annurev-med-043021-015237.html?itemId=/content/journals/10.1146/annurev-med-043021-015237&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Welsh KJ, Baumblatt J, Chege W et al. 2021. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine 39:253329–32
    [Google Scholar]
  2. 2.
    Cines DB, Bussel JB, Liebman HA et al. 2009. The ITP syndrome: pathogenic and clinical diversity. Blood 113:266511–21
    [Google Scholar]
  3. 3.
    Lee E-J, Cines DB, Gernsheimer T et al. 2021. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am. J. Hematol. 96:5534–37
    [Google Scholar]
  4. 4.
    Greinacher A, Thiele T, Warkentin TE et al. 2021. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384:222092–101
    [Google Scholar]
  5. 5.
    Schultz NH, Sørvoll IH, Michelsen AE et al. 2021. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384:222124–30
    [Google Scholar]
  6. 6.
    Scully M, Singh D, Lown R et al. 2021. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384:232202–11
    [Google Scholar]
  7. 7.
    See I, Su JR, Lale A et al. 2021. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 325:242448–56
    [Google Scholar]
  8. 8.
    Pishko AM, Cuker A. 2021. Thrombosis after vaccination with messenger RNA-1273: Is this vaccine-induced thrombosis and thrombocytopenia or thrombosis with thrombocytopenia syndrome?. Ann. Intern. Med. 174:101468–69
    [Google Scholar]
  9. 9.
    UK Med. Healthc. Prod. Regul. Agency 2022. Coronavirus vaccine—weekly summary of Yellow Card reporting https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting#yellow-card-reports. Accessed Mar. 15, 2022
    [Google Scholar]
  10. 10.
    Huynh A, Kelton JG, Arnold DM et al. 2021. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 596:7873565–69
    [Google Scholar]
  11. 11.
    Rauova L, Wang A, Yarovoi S et al. 2021. Vaccine-induced thrombocytopenia and thrombosis (VITT) antibodies recognize neutrophil-activating peptide 2 (NAP2) as well as platelet factor 4 (PF4): mechanistic and clinical implications. Blood 138:Suppl. 1292
    [Google Scholar]
  12. 12.
    Pavord S, Scully M, Hunt BJ et al. 2021. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N. Engl. J. Med. 385:181680–89
    [Google Scholar]
  13. 13.
    Klok FA, Pai M, Huisman MV et al. 2022. Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol 9:1e73–80
    [Google Scholar]
  14. 14.
    Warkentin TE. 2010. Fondaparinux: Does it cause HIT? Can it treat HIT?. Expert Rev. Hematol. 3:5567–81
    [Google Scholar]
  15. 15.
    Cuker A, Arepally GM, Chong BH et al. 2018. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2:223360–92
    [Google Scholar]
  16. 16.
    Bourguignon A, Arnold DM, Warkentin TE et al. 2021. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. N. Engl. J. Med. 385:8720–28
    [Google Scholar]
  17. 17.
    Uzun G, Althaus K, Singh A et al. 2021. The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia. Blood 138:11992–95
    [Google Scholar]
  18. 18.
    Patriquin CJ, Laroche V, Selby R et al. 2021. Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia. N. Engl. J. Med. 385:9857–59
    [Google Scholar]
  19. 19.
    Greinacher A, Langer F, Makris M et al. 2022. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J. Thromb. Haemost. 20:1149–56
    [Google Scholar]
  20. 20.
    Pavord S, Lester W, Makris M et al. 2021. Guidance from the Expert Haematology Panel (EHP) on COVID-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT) https://b-s-h.org.uk/media/20499/guidance-version-22-20210903.pdf. Accessed Mar. 15, 2022
    [Google Scholar]
  21. 21.
    Uaprasert N, Trithiphen S, Sukperm A et al. 2021. Safety of the second dose of the ChAdOx1 nCoV-19 vaccine in people with persistent anti-platelet factor 4 antibodies. Res. Pract. Thromb. Haemost. 5:82–3
    [Google Scholar]
  22. 22.
    US Cent. Dis. Control Prev 2022. Data and Statistics on Venous Thromboembolism https://www.cdc.gov/ncbddd/dvt/data.html
    [Google Scholar]
  23. 23.
    Off. Surgeon Gen 2008. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism Rep., Off. Surgeon Gen. Rockville, MD:
    [Google Scholar]
/content/journals/10.1146/annurev-med-043021-015237
Loading
/content/journals/10.1146/annurev-med-043021-015237
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error